Literature DB >> 2916331

Saturable binding sites mediate the entry of African swine fever virus into Vero cells.

A Alcamí1, A L Carrascosa, E Viñuela.   

Abstract

Binding experiments of 3H-labeled African swine fever virus to susceptible VERO cells have shown the presence of saturable binding sites for African swine fever virus on the plasma membrane. The Scatchard analysis of the binding data at equilibrium indicates the existence of about 10(4) cellular receptor sites per cell with a dissociation constant (Kd) of 70 pM. Virus entry into VERO cells is mediated by a saturable component, since tritiated African swine fever virus saturable binding and uptake were competed by the same amounts of unlabeled virus. Similarly, early viral protein synthesis and virus production were inhibited by concentrations of uv-inactivated virus that competed virus attachment to saturable binding sites, suggesting that specific receptors mediate the entry of African swine fever virus particles that initiate a productive infection in VERO cells. African swine fever virus binding to virus-resistant L cells was not mediated by saturable binding sites. As a result of the nonsaturable interaction the virus was not able to enter L cells and neither early viral protein synthesis nor viral DNA synthesis was detected, indicating that the absence of specific receptors for African swine fever virus is a factor that determines the resistance of L cells to the infection.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2916331     DOI: 10.1016/0042-6822(89)90281-x

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  20 in total

1.  African swine fever virus attachment protein.

Authors:  A L Carrascosa; I Sastre; E Viñuela
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

2.  Comparison of the sequence of the gene encoding African swine fever virus attachment protein p12 from field virus isolates and viruses passaged in tissue culture.

Authors:  A Angulo; E Viñuela; A Alcamí
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

3.  Amino acid sequence and structural properties of protein p12, an African swine fever virus attachment protein.

Authors:  A Alcamí; A Angulo; C López-Otín; M Muñoz; J M Freije; A L Carrascosa; E Viñuela
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

4.  General analysis of receptor-mediated viral attachment to cell surfaces.

Authors:  T J Wickham; R R Granados; H A Wood; D A Hammer; M L Shuler
Journal:  Biophys J       Date:  1990-12       Impact factor: 4.033

5.  Transcriptional mapping of a late gene coding for the p12 attachment protein of African swine fever virus.

Authors:  F Almazán; J M Rodríguez; A Angulo; E Viñuela; J F Rodriguez
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

6.  Inhibition of African swine fever virus binding and infectivity by purified recombinant virus attachment protein p12.

Authors:  A Angulo; E Viñuela; A Alcamí
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

7.  Fast and high-affinity binding of B-lymphotropic papovavirus to human B-lymphoma cell lines.

Authors:  M Herrmann; M Oppenländer; M Pawlita
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  Saturable attachment sites for polyhedron-derived baculovirus on insect cells and evidence for entry via direct membrane fusion.

Authors:  H M Horton; J P Burand
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

9.  The African swine fever virus virion membrane protein pE248R is required for virus infectivity and an early postentry event.

Authors:  Irene Rodríguez; María L Nogal; Modesto Redrejo-Rodríguez; María J Bustos; María L Salas
Journal:  J Virol       Date:  2009-09-30       Impact factor: 5.103

10.  Macrophage phagocytosis of foot-and-mouth disease virus may create infectious carriers.

Authors:  Rachael C Rigden; Carlos P Carrasco; Artur Summerfield; Kenneth C MCCullough
Journal:  Immunology       Date:  2002-08       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.